Trial site
Tulane Medical Center
New Orleans, Louisiana 70112, United StatesNot linked to an institution yet
- 4running trials
- 12closed trials
The trials here
What the 16 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 13 trials
- Phase 23 trials
- Phase 41 trial
- Status
- Completed9 trials
- Active, not recruiting2 trials
- Terminated2 trials
- Not yet recruiting1 trial
- Recruiting1 trial
- Withdrawn1 trial
- Lead sponsor
- Vertex Pharmaceuticals Incorporated3 trials
- American Heart Association1 trial
- Bayer1 trial
- Boehringer Ingelheim1 trial
- Calliditas Therapeutics Suisse SA1 trial
- and 9 more
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Terminated
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source
Completed
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
NCT05364424· Phase 1· Hoffmann-La Roche· Source
Completed
Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)
NCT05085977· Phase 1· Protara Therapeutics· Source
Completed
A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness
NCT05014672· Phase 2· Calliditas Therapeutics Suisse SA· Source
Completed
Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation
NCT05130268· Phase 4· American Heart Association· Source
Completed
A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation
NCT05076149· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Completed
A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)
NCT05033080· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Terminated
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
NCT04778397· Phase 3· Gilead Sciences· Source
Completed
A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy
NCT04266795· Phase 2· Takeda· Source
Completed
Fostering Shared Decision-making About Prostate Cancer Screening Among Clinicians and African American Men
NCT03869216· Xavier University of Louisiana.· Source
Completed
Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer
NCT03724747· Phase 1· Bayer· Source
Recruiting
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
NCT01351545· Center for International Blood and Marrow Transplant Research· Source
Contact: Elizabeth Fosberg, B.A.
Report an error